Tyrosine Kinase/Adaptors
Tyrosine kinase and adaptor inhibitors are compounds that target tyrosine kinases and their associated adaptor proteins, which play pivotal roles in cell signaling, growth, and differentiation. These inhibitors are essential tools in cancer research, as many tyrosine kinases are involved in the signaling pathways that drive tumor growth and metastasis. By inhibiting tyrosine kinases, these compounds can block critical signaling cascades, offering potential therapeutic strategies for various cancers and other diseases involving abnormal cell signaling. At CymitQuimica, we provide a comprehensive range of high-quality tyrosine kinase and adaptor inhibitors to support your research in oncology, molecular biology, and targeted therapy development.
Subcategories of "Tyrosine Kinase/Adaptors"
- ALK(135 products)
- CSF-1R(42 products)
- EGFR(553 products)
- Ephrin Receptor(25 products)
- FLT(87 products)
- Fibroblast Growth Factor Receptor (FGFR)(176 products)
- HER(5 products)
- Hck(3 products)
- IGF-1R(97 products)
- PDGFR(127 products)
- PYK2(7 products)
- Src(82 products)
- TAM Receptor(33 products)
- Tie-2(20 products)
- Trk receptor(54 products)
- Tyrosine Kinases(12 products)
- VEGFR(236 products)
- c-Fms(100 products)
- c-Kit(113 products)
- c-Met/HGFR(139 products)
- c-RET(60 products)
Show 13 more subcategories
Found 1016 products of "Tyrosine Kinase/Adaptors"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
MS 154N
CAS:MS 154N is a negative control for MS 154, binds WT/L858R EGFR tightly (Kd 3-4.3nM), doesn't trigger mutant EGFR degradation.Formula:C47H56ClFN8O8Color and Shape:SolidMolecular weight:915.45CSF1R-IN-7
CAS:CSF1R-IN-7 is a highly selective CSF-1R inhibitor with good brain penetration for treatment of diseases associated with microglia-mediated neuroinflammation.Formula:C22H22N6O3Purity:99.41% - 99.93%Color and Shape:SolidMolecular weight:418.45EphB1-IN-1
CAS:EphB1-IN-1 is a potent inhibitor of EphB1, exhibiting IC50 values of 3.0 nM for EphB1 G703C, 15 nM for EphB1 T697G, and 220 nM for EphB1 WT.Formula:C16H12Cl2N4O2Color and Shape:SolidMolecular weight:363.2MS 39
CAS:MS 39, a selective EGFR depressant, degrades mutant receptors in lung cancer lines without affecting wild-type. Effective in vitro and in mice.Formula:C55H71ClFN9O7SColor and Shape:SolidMolecular weight:1056.72EGFR-IN-67
CAS:EGFR-IN-67 (Compound 7d) is a potent inhibitor of EGFR with anticancer activity (IC 50 = 0.34 μM) [1].Formula:C18H17N3SColor and Shape:SolidMolecular weight:307.41Nimotuzumab
CAS:Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).Purity:95.00% - 98.5% (SDS-PAGE); 96.4% (SEC-HPLC)Color and Shape:LiquidMolecular weight:147.64 kDaEGA
CAS:EGA blocks the entry of a variety of other acid-dependent bacterial toxins and viruses into mammalian cells and can be used to treat infectious diseases.Formula:C16H16BrN3OPurity:98% - 99.6%Color and Shape:SolidMolecular weight:346.22DS21360717
CAS:DS21360717 is an effective oral tyrosine kinase inhibitor with anticancer activity and IC50 of 0.49 nM.Formula:C21H23N7OPurity:98%Color and Shape:SolidMolecular weight:389.45Limertinib
CAS:Limertinib (ASK120067) is a EGFR tyrosine kinase inhibitor targeting EGFR T790M, applicable for the study of non-small cell lung cancer.
Formula:C29H32ClN7O2Purity:97.44%Color and Shape:SolidMolecular weight:546.06NSC81111
CAS:NSC81111 shows anticaner effects which is a potent and orally active inhibitor of EGFR-TK (IC50 = 0.15 nM) [1].Formula:C19H16O4Color and Shape:SolidMolecular weight:308.33EGFR-IN-50
CAS:EGFR-IN-50, a potent EGFR blocker, hinders L858R mutation; GI50: 8 nM for TEL-EGFR-L858R, 6.03 μM for T790M-L858R; curbs cancer cell growth.Formula:C24H26BrN3O4S2Color and Shape:SolidMolecular weight:564.51EGFR-IN-5
CAS:EGFR-IN-5 inhibits EGFR & mutants; IC50: EGFR 10.4nM, L858R 1.1nM, L858R/T790M 34nM, L858R/T790M/C797S 7.2nM.
Formula:C31H38FN9OPurity:98.17%Color and Shape:SolidMolecular weight:571.69EGFR-IN-2
CAS:EGFR-IN-2 is a oral and mutation-selective EGFR inhibito,NSCLC, with high selectivity for resistant single and double mutant T790M.Formula:C26H33N9O3SPurity:98.52% - 99.79%Color and Shape:SolidMolecular weight:551.66Bezuclastinib
CAS:Bezuclastinib (CGT9486) is a novel, potent and highly selective tyrosine kinase and c-kit D816V inhibitor for the study of advanced mastocytosis.Formula:C19H17N5OPurity:99.55%Color and Shape:SolidMolecular weight:331.37NSC114126
CAS:NSC114126 is a potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.Formula:C22H20O4Color and Shape:SolidMolecular weight:348.39Gilteritinib hemifumarate
CAS:Gilteritinib hemifumarate (ASP2215 hemifumarate) is a potent ATP-competitive dual FLT3 (IC50: 0.29 nM) and AXL (IC50: 0.73 nM) inhibitor for the treatment of
Formula:C29H44N8O3C4H4O4Purity:99.78%Color and Shape:SolidMolecular weight:610.75EMI48
CAS:EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].Formula:C21H20N2O3Color and Shape:SolidMolecular weight:348.4EGFR-IN-39
CAS:EGFR-IN-39, an acrylamide, is a potent EGFR inhibitor and antitumor agent targeting NSCLC with low toxicity. See WO2021185348A1 for details.Formula:C24H25ClN6O3Color and Shape:SolidMolecular weight:480.95EGFR/HER2-IN-9
CAS:EGFR/HER2-IN-9, a compound inhibiting both EGFR and HER2, demonstrates potency with IC50 values of 3.2 nM for EGFR, 14 nM for HER2, and 8.3 nM against the EGFRFormula:C25H25ClFN5O4Color and Shape:SolidMolecular weight:513.95EMI56
CAS:EMI56, a derivative of EMI1, exhibits enhanced potency against mutant EGFR compared to EMI1. Additionally, EMI56 effectively inhibits EGFR triple mutants[1].Formula:C21H20N2O3Color and Shape:SolidMolecular weight:348.4
